<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123627</url>
  </required_header>
  <id_info>
    <org_study_id>TIMOVAL</org_study_id>
    <nct_id>NCT03123627</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.</brief_title>
  <official_title>Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Valganciclovir prophylaxis can be discontinued before 3 months in
      CMV-seropositive renal transplant recipients receiving induction thymoglobulin when
      developing CMV-specific cellular immunity after transplantation.

      Objective Meet the efficacy and safety of valganciclovir prophylaxis suspend in
      CMV-seropositive kidney transplant recipients with CD8 + cellular immunity CMV-specific
      transplant, receiving Thymoglobulin induction and maintain cellular immunity-specific CD8 +
      CMV after transplantation.

      Design: noninferiority clinical trial (study A) in CMV-seropositive kidney transplant
      recipients with CMV-specific cellular immunity pretransplant (Quantiferon reactive CMV)
      received induction with thymoglobulin

      Patients meeting inclusion criteria will be randomized to:

        -  Control Arm: valganciclovir prophylaxis until day +90 as recommended by the
           International Consensus document of the TTS (Transplantation 2013:96:333-360).

        -  Experimental arm: prophylaxis with valganciclovir and determination of CMV-specific
           cellular immunity day +15, +30, +45 and +60. Prophylaxis was discontinued when the
           patient developed CMV-specific cellular immunity. Patients who did not develop CMV
           specific immunity continue prophylaxis until day +90.

      Analysis: The incidence of CMV disease according to the strategy used was calculated using
      Kaplan-Meier curves that were compared using the log-rank test.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CMV disease at 12 months after transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation criteria for use in clinical trials</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Kidney Transplant Infection</condition>
  <arm_group>
    <arm_group_label>New profilaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Profilaxis recommended by TTS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>New profilaxis</intervention_name>
    <description>Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.</description>
    <arm_group_label>New profilaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Profilaxis recommended</intervention_name>
    <description>Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ&gt; 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).</description>
    <arm_group_label>Profilaxis recommended by TTS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant CMV-Seropositive

          -  CD8+ Tcell CMV especific pretransplant (CMV-reactive quantiferon pretrasplant)

          -  &gt; 18 years (adult)

          -  Receiving Thymoglobulin induction therapy

          -  Receiving Valganciclovir prophylaxis

        Exclusion Criteria:

          -  Multivisceral transplants including kidney-pancreas.

          -  HIV-infected Patients

          -  Patients who can not comply with the monitoring protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan Manuel Escandell Morales</last_name>
    <phone>0034677906567</phone>
    <email>juanmanuel.escandell@imibic.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurora Paez Vega</last_name>
    <phone>625591566</phone>
    <email>aumapave@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hosìtal Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel Escandell Morales</last_name>
      <phone>0034677906567</phone>
      <email>juanmanuel.escandell@imibic.org</email>
    </contact>
    <contact_backup>
      <last_name>Aurora Paez Vega</last_name>
      <phone>0034625591566</phone>
      <email>aumapave@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus, Seropositive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

